Pralatrexate and Oxaliplatin in Treating Patients With Unresectable or Metastatic Esophageal, Stomach, or Gastroesophageal Junction Cancer
Public ClinicalTrials.gov record NCT01178944. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Pralatrexate in Combination With Oxaliplatin in Advanced Esophago-gastric Cancer: A Phase II Trial With Predictive Molecular Correlates
Study identification
- NCT ID
- NCT01178944
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Roswell Park Cancer Institute
- Other
- Enrollment
- 35 participants
Conditions and interventions
Conditions
- Adenocarcinoma of the Gastroesophageal Junction
- Esophageal Undifferentiated Carcinoma
- Gastric Adenocarcinoma
- Gastric Squamous Cell Carcinoma
- Recurrent Esophageal Adenocarcinoma
- Recurrent Esophageal Squamous Cell Carcinoma
- Recurrent Gastric Carcinoma
- Stage IIIB Esophageal Adenocarcinoma
- Stage IIIB Esophageal Squamous Cell Carcinoma
- Stage IIIB Gastric Cancer
- Stage IIIC Esophageal Adenocarcinoma
- Stage IIIC Esophageal Squamous Cell Carcinoma
- Stage IIIC Gastric Cancer
- Stage IV Esophageal Adenocarcinoma
- Stage IV Esophageal Squamous Cell Carcinoma
- Stage IV Gastric Cancer
- Undifferentiated Gastric Carcinoma
Interventions
- Laboratory Biomarker Analysis Other
- Oxaliplatin Drug
- Pralatrexate Drug
Other · Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 31, 2010
- Primary completion
- Dec 31, 2014
- Completion
- Oct 31, 2015
- Last update posted
- Dec 12, 2017
2010 – 2015
United States locations
- U.S. sites
- 2
- U.S. states
- 1
- U.S. cities
- 2
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Roswell Park Cancer Institute | Buffalo | New York | 14263 | — |
| Rochester General Hospital | Rochester | New York | 14621 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01178944, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 12, 2017 · Synced May 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01178944 live on ClinicalTrials.gov.